Proliferative Radiation Retinopathy after Plaque Radiotherapy for Uveal Melanoma

Carlos Bianciotto; Carol L. Shields; Cesare Pirondini; Arman Mashayekhi; Minoru Furuta; Jerry A. Shields

doi:10.1016/j.ophtha.2009.10.015

Proliferative Radiation Retinopathy after Plaque Radiotherapy for Uveal Melanoma

Carlos Bianciotto, Carol L. Shields, Cesare Pirondini, Arman Mashayekhi, Minoru Furuta, Jerry A. Shields

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

Purpose: To determine risk factors, occurrence rate, management, and outcome of proliferative radiation retinopathy (PRR) after plaque radiotherapy for uveal melanoma. Design: Case-control study. Participants: Three thousand eight hundred forty-one patients who underwent plaque radiotherapy for uveal melanoma were entered into the study. Methods: Retrospective review of medical records. Main Outcome Measures: Proliferative radiation retinopathy after plaque radiotherapy for uveal melanoma. Results: Of 3841 eyes treated with plaque radiotherapy for uveal melanoma, PRR developed in 5.8% at 5 years and in 7% at 10 and 15 years using Kaplan-Meier analysis. The mean time to onset of PRR was 32 months (median, 30 months; range, 4-88 months). On univariate analysis, baseline factors predictive of PRR (P

Original language	English
Pages (from-to)	1005-1012
Number of pages	8
Journal	Ophthalmology
Volume	117
Issue number	5
DOIs	https://doi.org/10.1016/j.ophtha.2009.10.015
Publication status	Published - May 2010

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/j.ophtha.2009.10.015

Cite this

@article{4b90352b9bfd419abb74724d8a28f329,

title = "Proliferative Radiation Retinopathy after Plaque Radiotherapy for Uveal Melanoma",

abstract = "Purpose: To determine risk factors, occurrence rate, management, and outcome of proliferative radiation retinopathy (PRR) after plaque radiotherapy for uveal melanoma. Design: Case-control study. Participants: Three thousand eight hundred forty-one patients who underwent plaque radiotherapy for uveal melanoma were entered into the study. Methods: Retrospective review of medical records. Main Outcome Measures: Proliferative radiation retinopathy after plaque radiotherapy for uveal melanoma. Results: Of 3841 eyes treated with plaque radiotherapy for uveal melanoma, PRR developed in 5.8% at 5 years and in 7% at 10 and 15 years using Kaplan-Meier analysis. The mean time to onset of PRR was 32 months (median, 30 months; range, 4-88 months). On univariate analysis, baseline factors predictive of PRR (P",

author = "Carlos Bianciotto and Shields, {Carol L.} and Cesare Pirondini and Arman Mashayekhi and Minoru Furuta and Shields, {Jerry A.}",

year = "2010",

month = may,

doi = "10.1016/j.ophtha.2009.10.015",

language = "English",

volume = "117",

pages = "1005--1012",

journal = "Ophthalmology",

issn = "0161-6420",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - Proliferative Radiation Retinopathy after Plaque Radiotherapy for Uveal Melanoma

AU - Bianciotto, Carlos

AU - Shields, Carol L.

AU - Pirondini, Cesare

AU - Mashayekhi, Arman

AU - Furuta, Minoru

AU - Shields, Jerry A.

PY - 2010/5

Y1 - 2010/5

N2 - Purpose: To determine risk factors, occurrence rate, management, and outcome of proliferative radiation retinopathy (PRR) after plaque radiotherapy for uveal melanoma. Design: Case-control study. Participants: Three thousand eight hundred forty-one patients who underwent plaque radiotherapy for uveal melanoma were entered into the study. Methods: Retrospective review of medical records. Main Outcome Measures: Proliferative radiation retinopathy after plaque radiotherapy for uveal melanoma. Results: Of 3841 eyes treated with plaque radiotherapy for uveal melanoma, PRR developed in 5.8% at 5 years and in 7% at 10 and 15 years using Kaplan-Meier analysis. The mean time to onset of PRR was 32 months (median, 30 months; range, 4-88 months). On univariate analysis, baseline factors predictive of PRR (P

AB - Purpose: To determine risk factors, occurrence rate, management, and outcome of proliferative radiation retinopathy (PRR) after plaque radiotherapy for uveal melanoma. Design: Case-control study. Participants: Three thousand eight hundred forty-one patients who underwent plaque radiotherapy for uveal melanoma were entered into the study. Methods: Retrospective review of medical records. Main Outcome Measures: Proliferative radiation retinopathy after plaque radiotherapy for uveal melanoma. Results: Of 3841 eyes treated with plaque radiotherapy for uveal melanoma, PRR developed in 5.8% at 5 years and in 7% at 10 and 15 years using Kaplan-Meier analysis. The mean time to onset of PRR was 32 months (median, 30 months; range, 4-88 months). On univariate analysis, baseline factors predictive of PRR (P

UR - http://www.scopus.com/inward/record.url?scp=77951622412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951622412&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2009.10.015

DO - 10.1016/j.ophtha.2009.10.015

M3 - Article

C2 - 20079924

AN - SCOPUS:77951622412

VL - 117

SP - 1005

EP - 1012

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 5

ER -

Proliferative Radiation Retinopathy after Plaque Radiotherapy for Uveal Melanoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this